The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

White paper on cannabinoids and skin aging

2 Feb 2022 07:00

RNS Number : 4394A
Cellular Goods PLC
02 February 2022
 

Press release

 

2 February 2022

 

 

Cellular Goods PLC

 

("Cellular Goods" or "the Company")

 

 

Cellular Goods publish white paper exploring the role cannabinoids can play in preventing the signs of skin aging

 

Cellular Goods (LSE: CBX), a UK-based wellness company that provides premium products formulated with lab-made cannabinoids, today announces the release of a major new white paper, 'Cannabinoids for the Prevention of Aging', which explores the benefits cannabinoids, namely cannabidiol (CBD) and cannabigerol (CBG), can have for the skin by preventing the signs of aging.

Inherent aging and external factors, such as inflammation and exposure to UV light can cause wrinkles and fine lines, and make the skin lose its elasticity and volume. Within the cosmetics industry a wide range of skincare products rely on active ingredients such as Vitamin C, retinoids and exfoliating acids, to help address signs of aging, in a substantial anti-aging skincare market that is projected to reach US$47.8 billion by 2027.

To date Vitamin C, retinoids, and exfoliating acids are the active ingredients that have dominated this market, while they have proven to be effective in addressing signs of aging skin, they are also known to cause skin irritation and sensitivity. For the 50-60% of men and 60-70% of women who report some degree of sensitive skin, these side effects can hinder the long-term and routine use of these ingredients and therefore the ability of end users to benefit from regular and irritation-free use of anti-aging products. This has created a need for alternative products that harness ingredients that are effective in addressing skin aging without the worrying side-effects common to the current industry-standard ingredients.

Cellular Goods' white paper reveals that CBG, CBD and their blends are capable of counteracting the well-established aging effects of both UV exposure and inflammation, equally and in some cases more effectively than Vitamin C. This significant finding is made more impactful by the fact that Cellular Goods' products have been proven suitable for sensitive skin, thereby confirming that their cannabinoid formulations (unlike many other skincare products containing anti-aging ingredients, including Vitamin C) can be used without causing skin irritation.

Owing to these properties CBG and CBD are well positioned to emerge as key ingredients in the skincare market.

Cellular has incorporated these findings into its range of cannabinoid age prevention products, which have been dermatologically tested and shown to be suitable for sensitive skin. The first product in this range is Cellular Goods' Cannabinoid Face Serum, a breakthrough formula designed to prevent signs of aging that is the first CBG-powered skincare product in the UK.

The white paper is available to view here.

Anna Chokina, Chief Executive of Cellular Goods, said: "Cellular Goods is on a mission to become the most innovative listed wellness company and the release of today's white paper shows our commitment to the ground-breaking science that will drive the industry forward. CBD and CBG have very promising skincare applications and we are delighted to be able to share our findings. Delivering efficacy-led and research-backed products is at the heart of the Cellular brand ethos and this approach will ensure that our products take full advantage of all the benefits that lab-made cannabinoids can offer.

"We are proud to be the first to bring products formulated with CBG to the UK. CBG is the most promising cannabinoid for skincare applications and pioneering its use sets Cellular apart from the competition."

Alexia Blake, Head of Product Development and Product Research at Cellular Goods, said: "Cellular Goods is the first to offer science-backed skincare solutions that leverage the potent anti-inflammatory and antioxidant properties of high purity lab-made cannabinoids to provide consumers with targeted solutions for aging prevention.

"From sensitivity through to irritation, some of the active ingredients in traditional anti-aging products such as retinoids and Vitamin C have unpleasant side-effects that can prevent their regular use and impact those with sensitive skin. Our research, which has provided further insight into the properties and safety of cannabinoids, demonstrates that cannabinoids possess unique benefits that enable them to fill this gap and usher in a revolution in skincare."

For further information please contact:

 

Cellular Goods

Anna Chokina

Chief Executive

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Gabriela Amaya Garcia

Edward Daly

Charlie Hobbs

Salamander Davoudi

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 791 503 5294

+44 786 143 0057

+44 789 755 7112

+44 795 754 9906

 

Notes to Editors

'Cannabinoids for the Prevention of Aging' is authored by Alexia Blake, who leads Product Development and Product Research at Cellular Goods. She is a pioneer in the North American cannabis industry with a proven track record of developing efficacious products based on science and clinical evidence. Leveraging her food industry experience, she began her career in the cannabis space at MedReleaf Corp., one of the first Canadian producers of medical cannabis to receive a license from Health Canada. While at MedReleaf, the company became one of the largest global producers of legal cannabis and was eventually acquired in 2018 by Aurora for $2.5 billion. Alexia led the development of Aurora's global CBD portfolio for the health and wellness market before joining LAVVAN Inc., a leading company focused on commercialising high-quality cannabinoid ingredients produced using biosynthesis for the health, beauty, food, beverage and pharmaceutical markets.

About Cellular Goods PLC:

Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Function Better, Feel Better and Look Better. These three verticals encompass Cellular's premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATTMATMTIMMMT
Date   Source Headline
23rd Dec 20227:00 amRNSTR-1: Standard notification of major holdings
23rd Dec 20227:00 amRNSCellular Goods Annual Results
23rd Nov 20226:16 pmRNSTR-1: Standard notification of major holdings
2nd Nov 202210:34 amRNSTR-1: Standard notification of major holdings
24th Oct 20227:00 amRNSProducts launch on Debenhams.com
20th Oct 20227:00 amRNSLaunch of gift set collection for festive season
26th Sep 20227:00 amRNSProposed purchase of Cannaray Brands and Love CBD
23rd Sep 20225:49 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20225:47 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20225:42 pmRNSTR-1: Standard notification of major holdings
23rd Sep 20227:00 amRNSCellular Goods now shipping products to the USA
23rd Sep 20227:00 amRNSCellular Goods now shipping products to the USA
21st Sep 20222:06 pmRNSSecond Price Monitoring Extn
21st Sep 20222:00 pmRNSPrice Monitoring Extension
21st Sep 20227:00 amRNSLaunch of three new skincare products
6th Sep 20227:00 amRNSPublication of new white paper
17th Aug 20227:00 amRNSGrant of Share Options
16th Aug 20227:00 amRNSAppointment of new Chief Financial Officer
5th Aug 20224:40 pmRNSSecond Price Monitoring Extn
5th Aug 20224:35 pmRNSPrice Monitoring Extension
4th Aug 20229:05 amRNSSecond Price Monitoring Extn
4th Aug 20229:00 amRNSPrice Monitoring Extension
3rd Aug 20224:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
3rd Aug 20229:05 amRNSSecond Price Monitoring Extn
3rd Aug 20229:00 amRNSPrice Monitoring Extension
2nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
2nd Aug 202211:05 amRNSSecond Price Monitoring Extn
2nd Aug 202211:00 amRNSPrice Monitoring Extension
1st Aug 20222:00 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSUpdate on marketing initiatives and YouGov survey
11th Jul 20227:00 amRNSLaunch of minis
20th Jun 20227:00 amRNSLaunch of CBG and CBD petition
30th May 20227:00 amRNSInterim results
20th May 20227:00 amRNSTR-1: Standard notification of major holdings
20th May 20227:00 amRNSTR-1: Standard notification of major holdings
16th May 20222:05 pmRNSSecond Price Monitoring Extn
16th May 20222:00 pmRNSPrice Monitoring Extension
12th May 20227:00 amRNSBoard changes
28th Apr 20227:00 amRNSFirst patent application filed
28th Apr 20227:00 amRNSInvestor presentation
22nd Apr 20226:04 pmRNSUpdate on ingestibles product range
22nd Apr 20227:00 amRNSWhite paper on lab-produced cannabinoids
13th Apr 20227:00 amRNSUpdate on ingestibles product range
11th Apr 20227:00 amRNSUpdate on ingestibles products
7th Apr 202210:24 amRNSTR-1: Standard notification of major holdings
1st Apr 20222:05 pmRNSSecond Price Monitoring Extn
1st Apr 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.